胸部SMARCA4缺陷型未分化肿瘤的诊治进展
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v7i1.11789
Abstract
SMARCA4是第19号染色体上的基因,编码转录染色质因子BRG1。BRG1属于SWI/SNF染色质重塑复合物的核心成分。拥有多种生物学功能,包括基因表达、分化和转录的调节,并为其提供能量。胸部SMARCA 4缺陷型未分化肿瘤(SMARCA4-UT)是一种吸烟相关恶性肿瘤,恶性程度高,预后不良。传统的肺癌治疗模式对 SMARCA4-UT疗效不佳,新型治疗策略的出现或是解决问题的关键。本文将对SMARCA4-UT的临床病理特点和其治疗模式的探讨进行综述。
Keywords
SMARCA4缺陷型未分化肿瘤；诊断；治疗
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] Salvador Rodriguez-Nieto;Montse Sanchez-Cespedes. BRG1 and LKB1: tales of two tumor suppressor genes on chro mosome 19p and lung cancer.[J].Carcinogenesis.2009,Vol.30 (No.4):547-554.
[2] Shorstova T,Marques M,Su J, et al. SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors. Cancer Res.2019;79(10):2761-2774.
[3] Nambirajan A, Jain D. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor.Semin Diagn Pathol.2021;38(5):83-89.
[4] Yoshida A,Kobayashi E,Kubo T,et al. Clinicopathological and molecular characterization of SMARCA4-deficient thora cic sarcomas with comparison to potentially related entities. Mod Pathol.2017;30(6):797-809.
[5] Kawachi H, Kunimasa K, Kukita Y, et al. Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma.Immun otherapy. 2021;13(10):799-806.
[6] Shinno Y, Ohe Y; Lung Cancer Study Group of the Japan Clinical Oncology Group (JCOG). Thoracic SMARCA4-deficient undifferentiated tumor: current knowledge and future persp ectives.Jpn J Clin Oncol. 2024;54(3):265-270.
[7] Shain AH;Pollack JR.The spectrum of SWI/SNF mutations, ubiquitous in human cancers.[J].Plos One.2013,Vol.8(No.1): e55119
[8] Nambirajan A, Singh V, Bhardwaj N, Mittal S, Kumar S, Jain D.SMARCA4/BRG1-Deficient Non-Small Cell Lung Carcino mas: A Case Series and Review of the Literature.Arch Pathol Lab Med.2021;145(1):90-98.
[9] Lissanu Deribe Y, Sun Y, Terranova C, et al. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer.Nat Med. 2018;24(7):1047-1057.
[10] Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015.J Thorac Oncol.2022;17(3):362-387.
[11] Le Loarer F, Watson S, Pierron G,et al. SMARCA4 inact ivation defines a group of undifferentiated thoracic malign ancies transcriptionally related to BAF-deficient sarcomas. Nat Genet.2015;47(10):1200-1205.
[12] Sauter JL, Graham RP, Larsen BT, Jenkins SM, Roden AC, Bol and JM. SMARCA4-deficient thoracic sarcoma:a distinctive clinicop athological entity with undifferentiated rhabdoid morphology and aggressive behavior.Mod Pathol. 2017;30(10):1422-1432.
[13] Shen X, Yang Z, Li N. 68 Ga-DOTA-FAPI-04 PET/CT in the Detection of Thoracic SMARCA4-Deficient Undifferentiat ed Tumor.Clin Nucl Med. 2023;48(12):1102-1104.
[14] Rekhtman N,Montecalvo J,Chang JC,et al. SMARCA4-Defici ent Thoracic Sarcomatoid Tumors Represent Primarily SmokingRelated Undifferentiated Carcinomas Rather Than Primary Thorac ic Sarcomas.J Thorac Oncol. 2020;15(2):231-247.
[2] Shorstova T,Marques M,Su J, et al. SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors. Cancer Res.2019;79(10):2761-2774.
[3] Nambirajan A, Jain D. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor.Semin Diagn Pathol.2021;38(5):83-89.
[4] Yoshida A,Kobayashi E,Kubo T,et al. Clinicopathological and molecular characterization of SMARCA4-deficient thora cic sarcomas with comparison to potentially related entities. Mod Pathol.2017;30(6):797-809.
[5] Kawachi H, Kunimasa K, Kukita Y, et al. Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma.Immun otherapy. 2021;13(10):799-806.
[6] Shinno Y, Ohe Y; Lung Cancer Study Group of the Japan Clinical Oncology Group (JCOG). Thoracic SMARCA4-deficient undifferentiated tumor: current knowledge and future persp ectives.Jpn J Clin Oncol. 2024;54(3):265-270.
[7] Shain AH;Pollack JR.The spectrum of SWI/SNF mutations, ubiquitous in human cancers.[J].Plos One.2013,Vol.8(No.1): e55119
[8] Nambirajan A, Singh V, Bhardwaj N, Mittal S, Kumar S, Jain D.SMARCA4/BRG1-Deficient Non-Small Cell Lung Carcino mas: A Case Series and Review of the Literature.Arch Pathol Lab Med.2021;145(1):90-98.
[9] Lissanu Deribe Y, Sun Y, Terranova C, et al. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer.Nat Med. 2018;24(7):1047-1057.
[10] Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015.J Thorac Oncol.2022;17(3):362-387.
[11] Le Loarer F, Watson S, Pierron G,et al. SMARCA4 inact ivation defines a group of undifferentiated thoracic malign ancies transcriptionally related to BAF-deficient sarcomas. Nat Genet.2015;47(10):1200-1205.
[12] Sauter JL, Graham RP, Larsen BT, Jenkins SM, Roden AC, Bol and JM. SMARCA4-deficient thoracic sarcoma:a distinctive clinicop athological entity with undifferentiated rhabdoid morphology and aggressive behavior.Mod Pathol. 2017;30(10):1422-1432.
[13] Shen X, Yang Z, Li N. 68 Ga-DOTA-FAPI-04 PET/CT in the Detection of Thoracic SMARCA4-Deficient Undifferentiat ed Tumor.Clin Nucl Med. 2023;48(12):1102-1104.
[14] Rekhtman N,Montecalvo J,Chang JC,et al. SMARCA4-Defici ent Thoracic Sarcomatoid Tumors Represent Primarily SmokingRelated Undifferentiated Carcinomas Rather Than Primary Thorac ic Sarcomas.J Thorac Oncol. 2020;15(2):231-247.
Copyright © 2025 高歌, 张亚睿, 朱翠敏
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
